Pluri (PLUR) Competitors

Pluri (NASDAQ:PLUR) and ADC Therapeutics (NYSE:ADCT) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, media sentiment, risk, valuation, institutional ownership, analyst recommendations, earnings and community ranking.

Which has more volatility and risk, PLUR or ADCT?

Pluri has a beta of 1.95, suggesting that its stock price is 95% more volatile than the S&P 500. Comparatively, ADC Therapeutics has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.

Does the MarketBeat Community believe in PLUR or ADCT?

ADC Therapeutics received 62 more outperform votes than Pluri when rated by MarketBeat users.

Company	Underperform	Outperform
Pluri	N/A	N/A
ADC Therapeutics	Outperform Votes 62 68.89%	Underperform Votes 28 31.11%

Does the media favor PLUR or ADCT?

In the previous week, Pluri had 2 more articles in the media than ADC Therapeutics. MarketBeat recorded 4 mentions for Pluri and 2 mentions for ADC Therapeutics. Pluri's average media sentiment score of 0.57 beat ADC Therapeutics' score of -0.33 indicating that Pluri is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Pluri	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
ADC Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do institutionals & insiders have more ownership in PLUR or ADCT?

16.6% of Pluri shares are held by institutional investors. Comparatively, 41.1% of ADC Therapeutics shares are held by institutional investors. 10.2% of Pluri shares are held by company insiders. Comparatively, 4.1% of ADC Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Is PLUR or ADCT more profitable?

ADC Therapeutics has a net margin of -300.00% compared to Pluri's net margin of -3,551.49%. ADC Therapeutics' return on equity of 0.00% beat Pluri's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-3,551.49%	-2,778.13%	-83.61%
ADC Therapeutics	-300.00%	N/A	-61.33%

Do analysts rate PLUR or ADCT?

ADC Therapeutics has a consensus price target of $7.75, suggesting a potential upside of 436.33%. Given ADC Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe ADC Therapeutics is more favorable than Pluri.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
ADC Therapeutics	0 Sell rating(s)	0 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	3.00

Which has higher earnings & valuation, PLUR or ADCT?

Pluri has higher earnings, but lower revenue than ADC Therapeutics. ADC Therapeutics is trading at a lower price-to-earnings ratio than Pluri, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$678K	50.47	-$20.89M	-$5.60	-0.87
ADC Therapeutics	$70.84M	2.02	-$240.05M	-$1.65	-0.88

Summary

ADC Therapeutics beats Pluri on 11 of the 17 factors compared between the two stocks.